Clene Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLNN research report →
Companyclene.com
Clene Inc. , a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
- CEO
- Robert Etherington
- IPO
- 2018
- Employees
- 75
- HQ
- Salt Lake City, UT, US
Price Chart
Valuation
- Market Cap
- $71.12M
- P/E
- -2.40
- P/S
- 530.77
- P/B
- -4.27
- EV/EBITDA
- -3.64
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -182.09%
- Op Margin
- -15535.07%
- Net Margin
- -25009.70%
- ROE
- 233.93%
- ROIC
- -118.10%
Growth & Income
- Revenue
- $200.00K · -41.52%
- Net Income
- $-26,173,000 · 33.57%
- EPS
- $-2.65 · 53.26%
- Op Income
- $-23,083,000
- FCF YoY
- 12.91%
Performance & Tape
- 52W High
- $13.50
- 52W Low
- $2.28
- 50D MA
- $6.14
- 200D MA
- $6.40
- Beta
- 0.89
- Avg Volume
- 499.02K
Get TickerSpark's AI analysis on CLNN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 11, 26 | Ugwumba Chidozie | sell | 22,177 |
| May 12, 26 | Ugwumba Chidozie | sell | 73,296 |
| May 1, 26 | Ugwumba Chidozie | sell | 5,795 |
| May 4, 26 | Ugwumba Chidozie | sell | 72,884 |
| Apr 28, 26 | Ugwumba Chidozie | sell | 1,591 |
| Apr 29, 26 | Ugwumba Chidozie | sell | 12,170 |
| Apr 30, 26 | Ugwumba Chidozie | sell | 5,736 |
| Apr 20, 26 | Ugwumba Chidozie | sell | 4,318 |
| Apr 21, 26 | Ugwumba Chidozie | sell | 61,345 |
| Apr 15, 26 | Ugwumba Chidozie | sell | 6,374 |
Our CLNN Coverage
We haven't published any research on CLNN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CLNN Report →